INTRODUCTION: The ACOSOG Z0011 trial has been described as practice-changing. The goal of this study was to determine the impact of the trial on surgeon practice patterns at our institution. METHODS: This is a review of practice patterns comparing the year before release of Z0011 to the year after an institutional multidisciplinary meeting discussing the results. Patients meeting Z0011 inclusion criteria were identified. Clinicopathologic data were compared between the cohorts. RESULTS: There were 658 patients with clinical T1-2 tumors planned for breast conservation: 335 in the pre-Z0011 cohort and 323 post-Z0011. Sixty-two (19 %) patients were sentinel lymph node (SLN) positive in the pre-Z0011 group versus 42 (13 %) post-Z0011 (p = 0.06). Before Z0011, 85 % (53/62) of SLN-positive patients underwent axillary node dissection (ALND) versus 24 % (10/42) after Z0011 (p < 0.001). After Z0011, surgeons were more likely to perform ALND on patients with larger tumors (2.2 vs. 1.5 cm, p = 0.09), lobular histology (p = 0.01), fewer SLNs (1 vs. 3, p = 0.09), larger SLN metastasis size (4 vs. 2.5 mm, p = 0.19), extranodal extension present (20 vs. 6 %, p = 0.16), or a higher probability of positive non-SLNs (p = 0.03). Surgeons were less likely to perform intraoperative nodal assessment post-Z0011 (26 vs. 69 %, p < 0.001) resulting in decreased median operative times for SLN-negative patients (79 vs. 92 min, p < 0.001). CONCLUSIONS: Surgeons at our institution have implemented Z0011 results for the majority of patients; however, clinicopathologic factors still impact the decision to perform ALND. Z0011 results have significantly impacted practice by decreasing rates of ALND, use of intraoperative nodal evaluation, and operative times.
INTRODUCTION: The ACOSOG Z0011 trial has been described as practice-changing. The goal of this study was to determine the impact of the trial on surgeon practice patterns at our institution. METHODS: This is a review of practice patterns comparing the year before release of Z0011 to the year after an institutional multidisciplinary meeting discussing the results. Patients meeting Z0011 inclusion criteria were identified. Clinicopathologic data were compared between the cohorts. RESULTS: There were 658 patients with clinical T1-2 tumors planned for breast conservation: 335 in the pre-Z0011 cohort and 323 post-Z0011. Sixty-two (19 %) patients were sentinel lymph node (SLN) positive in the pre-Z0011 group versus 42 (13 %) post-Z0011 (p = 0.06). Before Z0011, 85 % (53/62) of SLN-positive patients underwent axillary node dissection (ALND) versus 24 % (10/42) after Z0011 (p < 0.001). After Z0011, surgeons were more likely to perform ALND on patients with larger tumors (2.2 vs. 1.5 cm, p = 0.09), lobular histology (p = 0.01), fewer SLNs (1 vs. 3, p = 0.09), larger SLN metastasis size (4 vs. 2.5 mm, p = 0.19), extranodal extension present (20 vs. 6 %, p = 0.16), or a higher probability of positive non-SLNs (p = 0.03). Surgeons were less likely to perform intraoperative nodal assessment post-Z0011 (26 vs. 69 %, p < 0.001) resulting in decreased median operative times for SLN-negative patients (79 vs. 92 min, p < 0.001). CONCLUSIONS: Surgeons at our institution have implemented Z0011 results for the majority of patients; however, clinicopathologic factors still impact the decision to perform ALND. Z0011 results have significantly impacted practice by decreasing rates of ALND, use of intraoperative nodal evaluation, and operative times.
Authors: Elizabeth A Mittendorf; Kelly K Hunt; Judy C Boughey; Roland Bassett; Amy C Degnim; Robyn Harrell; Min Yi; Funda Meric-Bernstam; Merrick I Ross; Gildy V Babiera; Henry M Kuerer; Rosa F Hwang Journal: Ann Surg Date: 2012-01 Impact factor: 12.969
Authors: Savitri Krishnamurthy; Nour Sneige; Deepak G Bedi; Beth S Edieken; Bruno D Fornage; Henry M Kuerer; S Eva Singletary; Kelly K Hunt Journal: Cancer Date: 2002-09-01 Impact factor: 6.860
Authors: Gary H Lyman; Armando E Giuliano; Mark R Somerfield; Al B Benson; Diane C Bodurka; Harold J Burstein; Alistair J Cochran; Hiram S Cody; Stephen B Edge; Sharon Galper; James A Hayman; Theodore Y Kim; Cheryl L Perkins; Donald A Podoloff; Visa Haran Sivasubramaniam; Roderick R Turner; Richard Wahl; Donald L Weaver; Antonio C Wolff; Eric P Winer Journal: J Clin Oncol Date: 2005-09-12 Impact factor: 44.544
Authors: Jeremy Setton; Hiram Cody; Lee Tan; Monica Morrow; Clifford Hudis; Jeffrey Catalano; Beryl McCormick; Simon Powell; Alice Ho Journal: Cancer Date: 2011-08-31 Impact factor: 6.860
Authors: Armando E Giuliano; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow; Karla Ballman Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Min Yi; Sharon Hermes Giordano; Funda Meric-Bernstam; Elizabeth A Mittendorf; Henry M Kuerer; Rosa F Hwang; Isabelle Bedrosian; Loren Rourke; Kelly K Hunt Journal: Ann Surg Oncol Date: 2010-09-19 Impact factor: 5.344
Authors: Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow Journal: JAMA Date: 2011-02-09 Impact factor: 56.272
Authors: B Fisher; M Bauer; R Margolese; R Poisson; Y Pilch; C Redmond; E Fisher; N Wolmark; M Deutsch; E Montague Journal: N Engl J Med Date: 1985-03-14 Impact factor: 91.245
Authors: Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King Journal: Curr Probl Surg Date: 2016-11-29 Impact factor: 1.909
Authors: Reshma Jagsi; Manjeet Chadha; Janaki Moni; Karla Ballman; Fran Laurie; Thomas A Buchholz; Armando Giuliano; Bruce G Haffty Journal: J Clin Oncol Date: 2014-08-18 Impact factor: 44.544
Authors: Etin-Osa O Osa; Keith DeWyngaert; Daniel Roses; James Speyer; Amber Guth; Deborah Axelrod; Maria Fenton Kerimian; Judith D Goldberg; Silvia C Formenti Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-24 Impact factor: 7.038
Authors: Cecilia T Ong; Samantha M Thomas; Rachel C Blitzblau; Oluwadamilola M Fayanju; Tristen S Park; Jennifer K Plichta; Laura H Rosenberger; Terry Hyslop; E Shelley Hwang; Rachel A Greenup Journal: Ann Surg Oncol Date: 2017-09-06 Impact factor: 5.344